IPM Take
Alzheimer’s medicine is becoming a diagnostic infrastructure problem. The old clinical conversation, built around memory tests and probability, is giving way to amyloid, tau, blood biomarkers and imaging pathways that can define who enters treatment, who enters trials and who remains outside the system.
Tauklarify’s FDA approval is important because tau pathology is not a decorative detail in Alzheimer’s disease. It helps describe where the disease is biologically active and clinically meaningful. But every new diagnostic gate creates an access question. If tau PET becomes important for research, treatment selection or clinical confidence, health systems need to decide whether it will be a precision tool or another expensive filter.
Executive Summary
Lantheus announced FDA approval of Tauklarify, florquinitau F 18 injection, also known as MK-6240, a tau PET imaging agent for adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify tau neurofibrillary tangle pathology.
The approval was supported by two blinded read studies using PET images from more than 500 subjects drawn from three clinical trials. Study 1 reported positive percent agreement across readers ranging from 80% to 88% and negative percent agreement from 98% to 99%. Study 2 reported positive percent agreement from 68% to 82% and negative percent agreement from 93% to 99%. Safety was evaluated in 1,734 subjects, with the most common adverse reactions including headache, nausea and injection-site reactions.
The approved indication is diagnostic. The safety and effectiveness of Tauklarify have not been established for evaluating non-Alzheimer’s disease tauopathies, and a negative or positive scan does not by itself settle all clinical uncertainty.
Why it matters
- Patients / advocates: More precise diagnosis can reduce uncertainty, but patients need counselling, follow-up and equitable access to specialised testing.
- Clinicians: Tau PET may help refine Alzheimer’s evaluation, especially alongside amyloid and other biomarkers, but results still require clinical interpretation.
- Diagnostics / pathology: The approval reflects the increasing centrality of imaging biomarkers in Alzheimer’s pathways.
- Payers: Coverage decisions will determine whether tau PET is available broadly or reserved for better-resourced settings.
Alzheimer’s disease is no longer being defined only at the bedside. It is being defined in laboratories, imaging suites and specialist pathways that can see biology before a conversation with a patient fully captures what is happening. That is scientific progress, but it is also a shift in power. The more diagnosis depends on advanced testing, the more access to those tests shapes who receives timely and accurate care.
Tauklarify adds another layer to that architecture. A tau PET scan can help identify neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer’s disease, complementing amyloid testing and other clinical assessments. In a field moving toward earlier diagnosis and disease-modifying treatment, that information may become increasingly valuable for trials, treatment decisions and research stratification.
But diagnostic precision can widen inequity if systems treat the technology as self-implementing. PET capacity is not evenly distributed. Referral pathways differ by region. Insurance coverage, specialist availability and health literacy can determine whether a patient reaches the test at all. A tool that helps define disease biology may still fail the patient if the pathway around it remains uneven.
The approval should therefore be read as both a scientific and system-readiness milestone. Alzheimer’s care is entering a world in which tau, amyloid and blood-based biomarkers will increasingly decide who is visible to medicine. The political question is whether visibility will be available to all patients or mainly to those close enough to the right centres.
